Latest Biotechnology, Pharmaceutical and Healthcare Channels on BioPortfolio

Anti-Fzd7 (vantictumab, OMP-18R5) Vantictumab is OncoMed’s lead program in the Wnt pathway. Screened against the Frizzled 7 receptor, the antibody binds a conserved epitope on five of the Frizzled receptors. It has been shown in preclinical studies to induce tumor cell differentiation. Vantictumab entered Phase 1 clinical testing in 2011. Vantictumab is a monoclonal antibody optimized...

AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Preclinical studies have shown that AUT00063 has the potential to reduce symptoms of age-related hearing loss and tinnitus, and may also help to prevent hearing loss caused by noise trauma. Safety and to...

Veregen® is an ointment used to treat external genital warts. In the USA, Germany, Austria, Spain, Switzerland and Serbia, Veregen® is already marketed by our partners. Sales and marketing partnerships are also in place for this drug in a large number of other countries in Europe, Asia and America. An overview of our partners can be found here. The sales generated with Veregen® are c...

Eligard® is a hormone compound for the treatment of advanced, hormone-dependent prostate cancer. The active ingredient (leuprolide acetate) significantly reduces the level of the male sex hormone testosterone, thus suppressing testosterone-dependent tumor growth. The established active ingredient is combined with a novel drug delivery system known as Atrigel® depot technology. The liquid...

KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory conditions. KIACTA™ is partenered with global private equity firm Auven Therapeutics (previously Celtic Therapeutics). Patients are currently being enrolled in a Phase III Confirmatory Study for K...

The SureSeq Solid Tumour Panel Sequencing Service utilises an enrichment panel comprising the full coding regions of 58 prioritised cancer genes. The aim of the panel is to improve cancer care by providing individualised patient profiles facilitating the implementation of personalised treatment strategies. The panel was research-validated for use with fresh, frozen and formalin-fixed, paraffin-e...

Auxogyn’s non-invasive Early Embryo Viability Assessment Test (Eeva) may improve in vitro fertilization (IVF) outcomes by providing IVF clinics and patients with objective information on embryo viability. Eeva’s proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division timing parameters. With Eeva’s quantitative...

Paroxysmal supraventricular tachycardia (PSVT) is episodes of rapid heart rate that start in a part of the heart above the ventricles. "Paroxysmal" means from time to time. The heart will suddenly start racing, then stop or slow down abruptly.  Episodes can last for seconds, minutes, hours or (in rare cases) days. They may occur regularly, several times a day, or very infrequent...

New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases. Xofigo shown in a pivotal phase III trial to significantly improve overall survival. Xofigo® with the active ingredient radium 223 dichloride (radium 223) is an alpha particle-emitting radioactive therapeutic agent with an anti-tumor effect on bone metastases. Radium 223 mimics calcium and forms...

Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid that will bind to the messenger RNA produced by that gene and inactivate it, effectively turning that gene "off". This is because mRNA has to be single strande...

Lupus : A major unmet medical need Lupus is a chronic and severe autoimmune disease in which the immune system produces antibodies to cells within the body leading to widespread inflammation and tissue damage. It may affect multiple organ systems, including the skin, the joints, the heart, the lungs and the kidneys. It can result in arthritis, kidney failure, cardio-vascular and pulmonary prob...

Therapies targeting TNF have already demonstrated efficacy across a wide range of inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondulitis, psoriasis and Crohn’s disease. The target market for Kinoids currently in development is estimated at over $24 billion, with potential to reach still broader markets (Source: LaMerie 2012). Although...

A glycoengineered, fully humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher bindin...

UroGenRA is a CGI custom-designed oligonucleotide array for implementation within a clinical laboratory as an array CGH-based diagnostic/prognostic tool for kidney, prostate, and bladder cancers. It was designed to detect gains and losses that frequently occur in these three cancer types and that have the potential to differentially diagnose and/or stratify patients to assist and guide clinical...

UGenRA is a CGI custom-designed oligonucleotide array designed to detect gains and losses of genomic material in endometrial, ovarian, and cervical cancers. Endometrial hyperplasia is a precursor lesion of endometriod endometrial carcinoma (EEC) and since about 50% of women with atypical hyperplasia also have concurrent EEC, it is important to identify those precursor lesions more likely to prog...

Mature B-cell neoplasms arise in B-cells that have entered germinal centers within lymph nodes as part of the immune response. They display great heterogeneity at the clinical, pathologic, and genetic levels and represent 6-7% and 5-6% of all new estimated cancer cases and deaths respectively in the US in 2009. They are the fifth most common neoplasm in both males and females, and of the 103,960...

Fluorescent in situ hybridization (FISH) is a sensitive and accurate technique that allows the detection of chromosome aberrations. In this method, a single-stranded fluorescent-labeled nucleic acid sequence (probe) complementary to a target genomic sequence is hybridized to metaphase chromosomes and interphase nuclei to detect the presence and absence of a given abnormality. FISH complements tr...

Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronaviruses are a large family of viruses that includes viruses that may cause a range of illnesses in humans, from the common cold to SARS. Viruses of this family also cause a number of animal diseases. N...

Avian influenza A H7 viruses are a group of influenza viruses that normally circulate among birds. The avian influenza A(H7N9) virus is one subgroup among the larger group of H7 viruses. Although some H7 viruses (H7N2, H7N3 and H7N7) have occasionally been found to infect humans, no human infections with H7N9 viruses have been reported until recent reports from China.

For optimal treatment in cancerology, clinicians need specific, precise, sensitive methods to quantify treatment response, monitor residual disease and detect early recurrence in patients. Residual disease monitoring has become common practice in many haematological cancers (e.g. leukaemia), meaning decisions on personalised treatment can be taken. All this has been possible because of the prese...

At OncoDNA, our philosophy is to provide the most suitable test in terms of rapidity and cost. That’s why we follow a 3 tier approach to find tumour mutations which can respond to new cancer therapies,. We always do the test OncoDEEP DX version first. This initial test is linked to all the targeted anti-cancer drugs currently on the market in Europe. If we don’t discover any mutatio...

Eliglustat acts at a level above the defective enzyme in Gaucher disease and reduces the amount of a toxic metabolite (glucosylceramide) that is the target of enzyme replacement therapy.

Lemtrada (alemtuzumab) is being developed by Sanofi in collaboration with Bayer Healthcare for the treatment of relapsing multiple sclerosis.

KYNAMRO (mipomersen sodium) injection is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Lyxumia® is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is released within minutes after eating a meal. It is known to suppress glucagon secretion from pancreatic alpha cells and stimulate glucose-dependent insulin secretion by pancreatic beta cells....